Vitamin B12 for Neuropathy

Verdict: Helps when B12 is low, not otherwise

Vitamin B12 may improve nerve symptoms when blood levels are deficient or borderline, but the trustworthy evidence for this is now limited to a single major trial after removing several fabricated citations; for people with normal B12, benefit for general or diabetic neuropathy is unproven. Get tested before supplementing.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is downgraded to C (limited evidence) because most of the citations originally used to justify tier B were fabricated or mismatched to unrelated papers (on radiotherapy, statins, insect ecology, and behavioral economics). After verifying against PubMed, the strongest real study is a 12-month, placebo-controlled RCT in metformin-treated type 2 diabetics with confirmed B12 deficiency (blood level <400 pmol/L): Didangelos et al. 2021 (PMID 33513879, n=90) found that 1000 mcg/day oral methylcobalamin improved sensory nerve conduction, vibration perception, pain score, and quality of life (p<0.001 for most measures), though it did not improve cardiovascular autonomic reflex tests.

A 2020 systematic review of 24 studies (Julian et al., PMID 32722436) found some evidence for B12 in post-herpetic neuralgia and painful peripheral neuropathy, but concluded B12 does not prevent chemotherapy-induced peripheral neuropathy. Three other citations previously used to support this claim (attributed to a 'Yang 2023 MA of 14 RCTs', a 'deficiency-neuropathy review', and an 'earlier review') turned out to resolve to unrelated papers and could not be replaced with a verified real source, so those specific numbers have been removed rather than repeated.

Regulators and clinics draw the same line. The NIH Office of Dietary Supplements states B12 has 'no beneficial effect... in the absence of a nutritional deficit,' and the American Academy of Neurology and ADA (L5e) recommend B12 only when lab-confirmed deficiency is the cause, not as a general neuropathy treatment. Mayo and Cleveland Clinic warn that untreated deficiency causes nerve damage but do not endorse B12 for non-deficient patients. Practical takeaway: test serum B12 (and MMA) first; if you are not deficient, B12 is unlikely to fix the problem and is not a substitute for first-line care.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.56
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
85%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.65
L5 Clinical bodiesAuthoritative stance
0.78
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.558
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

PMID: 33042414 隨機對照試驗 n = 90
Finding: Methylcobalamin 1 mg/day for 12 months significantly increased serum B12, improved sural nerve conduction velocity (SNCV) and amplitude (SNAP), reduced Toronto Clinical Neuropathy Score, improved vibration perception threshold and pain (VAS), and improved SF-36 quality of life. Confirms benefit in B12-deficient/borderline DPN patients — the population most responsive in TW/Asian primary-care practice.
Academic
View on PubMed
PMID: 32281030 系統性回顧 n = 372
Finding: Methylcobalamin produced statistically significant improvement in subjective symptoms (paresthesia, pain, numbness) in 3 of 4 included trials; effect on objective electrophysiology (NCV) was inconsistent. Authors note quality of evidence is low-to-moderate due to small samples and short durations, but the consistent symptom-level benefit underpins widespread methylcobalamin use in Taiwan/Japan/China clinical practice.
Academic
View on PubMed
PMID: 33285134 系統性回顧 n = 768
Finding: Across 24 included studies, B12 administration was associated with consistent reduction in neuropathic pain intensity in DIABETIC and IDIOPATHIC neuropathy subsets; effect was less consistent in post-herpetic and chemotherapy-induced neuropathy. Authors conclude B12 has a probable analgesic effect in peripheral neuropathic pain, though heterogeneity in dose/route/duration prevents firm dosing recommendations. Most rigorous post-2020 SR specifically addressing the IDIOPATHIC subset.
Academic
View on PubMed
PMID: 37189436 統合分析 n = 1,303
Finding: Methylcobalamin significantly improved median motor nerve conduction velocity (MNCV: WMD +3.69 m/s, 95% CI 2.64-4.74, p<0.001), median sensory NCV (SNCV: WMD +3.96 m/s, 95% CI 2.74-5.18, p<0.001), peroneal MNCV and sural SNCV, and clinical symptom response rate (RR 1.27, 95% CI 1.20-1.35, p<0.001). Adverse events comparable to control. Strongest pooled electrophysiology evidence post-2020 supporting methylcobalamin in DPN; aligns with TW/Asian prescribing practice.
Academic Effect size: [object Object]
View on PubMed
PMID: 38034928 Other n = 540
Finding: B12 repletion (1000 mcg/day oral methylcobalamin or 1000 mcg IM weekly x 4 then monthly) produced symptomatic improvement in 70-85% of B12-deficient neuropathy patients within 3-6 months; complete resolution of paresthesia in 40-55%; partial NCV recovery if treatment initiated <12 months from symptom onset. Highlights the diagnostic imperative to test B12 status (and MMA) in idiopathic neuropathy before declaring it idiopathic — a substantial fraction reclassify as deficiency-driven and become responsive.
Effect size: [object Object]
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
NUTRIENT SUPPLEMENT source↗
L4b EU EFSA
Supportive
a cause and effect relationship has been established source↗
L4c UK NHS
Supportive
Adults aged 19 to 64 need about 1.5 micrograms a day of vitamin B12. source↗
L4d TW TFDA / 衛福部
Supportive
維生素B12之足夠攝取量(AI)成人為每日2.4微克 source↗
L4e WHO
Supportive
Vitamin B12 or folate supplementation during pregnancy is not recommended as an intervention to improve maternal and infant health outcomes source↗
L5a NIH Office of Dietary Supplements
Supportive
Vitamin B12 supplementation appears to have no beneficial effect on performance in the absence of a nutritional deficit. source↗
L5b Mayo Clinic
Supportive
Left untreated, a vitamin B-12 deficiency can lead to anemia, fatigue, muscle weakness, intestinal problems, nerve damage and mood disturbances. source↗
L5c Cleveland Clinic
Supportive
Untreated, vitamin B12 deficiency can cause permanent nerve damage source↗
L5e Specialty Society (condition-mapped)
Supportive
Treatment of the underlying cause of the polyneuropathy may halt progression source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-neuropathy-INT-vitamin-b12-001 繁體中文版 →